Protagonist Therapeutics to replace Encore Wire in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA is acquiring Encore Wire in a deal expected to be completed soon pending final conditions.
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/5/2024 | $58.00 | Outperform | Wedbush | |
| 9/24/2024 | $65.00 | Buy | TD Cowen | |
| 9/9/2024 | $60.00 | Buy | Truist | |
| 10/30/2023 | $32.00 | Overweight | CapitalOne | |
| 10/11/2023 | $235.00 | Market Outperform | CJS Securities | |
| 5/25/2023 | $30.00 → $40.00 | Buy | Jefferies | |
| 8/25/2022 | $21.00 | Mkt Outperform | JMP Securities | |
| 2/11/2022 | $55.00 | Buy | BTIG |
Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results.Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274The webcast link for the event can
NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor in plaque psoriasisICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24ICONIC-TOTAL achieved its primary endpoint of IGA score of 0 or 1 at week 16 in patients with plaque psoriasis in difficult-to-treat areasProtagonist has earned a $165 million milestone under the terms of recently amended agreement, inclusive of $50 million in accelerated pay
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)
JP Morgan analyst Brian Cheng maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $39 to $48.
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. (NYSE:T) rose during Wednesday's session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro. AT&T shares gained 3.1% to $18.78 on Wednesday. Here are some other big stocks recording gains in today’s session. PROG Holdings, Inc. (NYSE:PRG) shares jumped 20.4% to $41.71 after the company reported better-than-expected s
8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)
10-Q - Protagonist Therapeutics, Inc (0001377121) (Filer)
8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)
Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases."We are extremely pleased to nominate development candidate PN-881, a promising potential best-in-class oral peptide IL
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results.Conference Call and Webcast DetailsThe dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are:US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274The webcast link for the event can
Encore Wire Corporation (NASDAQ Global Select: WIRE) announced today that the Company's Board of Directors has declared a cash dividend. Daniel L. Jones, Chairman, President and Chief Executive Officer of Encore Wire Corporation, said, "This two-cent per share dividend will be paid on July 19, 2024 to stockholders of record at the close of business on July 5, 2024." Encore Wire Corporation is a leading manufacturer of a broad range of copper and aluminum electrical wire and cables, supplying power generation and distribution solutions to meet our customers' needs today and in the future. The Company focuses on maintaining a low-cost of production while providing exceptional customer ser
Wedbush initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $58.00
TD Cowen initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $65.00
Truist initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $60.00
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery,
NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 3, 2024 S&P SmallCap 600 Addition Protagonist Therapeutics PTGX Health Care S&P SmallCap 600 Deletion Encore Wire WIRE Industrials For more information a
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)